Sapreme Technologies

What Sapreme Technologies does

Sapreme Technologies (legally Sapreme Development B.V., rebranding to Sapreme Therapeutics B.V. effective June 1, 2026) is a preclinical-stage biotechnology company headquartered at Utrecht Science Park in the Netherlands. The company is developing next-generation RNA therapeutics for patients with genetically driven diseases, with a particular focus on neuromuscular conditions (notably Duchenne muscular dystrophy, the lead program positioned as a potential best-in-class therapy) and cardiometabolic diseases.

Sapreme's core asset is its proprietary endosomal escape technology platform, branded SPT, built around chemically modified glycosylated triterpenoids — plant secondary metabolites engineered to enhance intracellular delivery of large therapeutic molecules such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). The technology is designed to remain inactive in circulation and, via a pH-driven mechanism, enable receptor-targeted release of therapeutic cargo from endosomes into the cytoplasm in liver and extrahepatic tissues including muscle, heart, and brain. The company cites proof-of-concept data in rodents and non-human primates.

As a preclinical company with no commercial products, Sapreme has not yet disclosed a pricing model or product revenue. Its commercial model is oriented toward strategic co-development partnerships with select pharma and biotech companies, supplemented by internal pipeline development. The company has raised $17 million in a Series A round (October 2021, Aglaia BioMedical Ventures), operates with 11-50 employees, and is led by CEO Marco Timmers (appointed May 2024) alongside founder/CSO Ruben Postel, with a Scientific Advisory Board covering RNA delivery and neuromuscular disease expertise.

Name

Sapreme Technologies

Legal name

Sapreme Development B.V.

Website

https://sapreme-technologies.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Sapreme Technologies is a preclinical-stage Dutch biotech developing a proprietary endosomal escape platform (SPT) to deliver RNA therapeutics (ASOs and siRNAs) to liver and extrahepatic tissues, with a lead program targeting Duchenne muscular dystrophy and a pipeline spanning neuromuscular and cardiometabolic diseases pursued via pharma partnerships.

Ownership category

akta.pro rank

Product category

RNA Therapeutics Delivery Technology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE)

Keywords

• RNA therapeutics delivery
• Endosomal escape technology
• Oligonucleotide delivery platform
• Targeted intracellular delivery
• Genetic disease therapeutics

Headquarters

HQ city

Bilthoven

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Sapreme is a preclinical-stage biotechnology company developing a proprietary endosomal escape technology platform (SPT) that enables targeted intracellular delivery of large molecule RNA therapeutics such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). The company is building a therapeutic pipeline anchored by a lead program designed as a best-in-class therapy for Duchenne muscular dystrophy, and pursues strategic co-development partnerships with pharma/biotech companies to advance its RNA therapeutics programs.

Product overview

Sapreme is a preclinical-stage biotech company developing a proprietary endosomal escape technology platform (SPT) for targeted delivery of RNA therapeutics. The SPT Platform enables delivery of large molecules such as ASOs and siRNAs to intracellular targets in liver and extrahepatic tissues including muscle, heart, and brain. The company is building a pipeline of therapeutic applications, with its lead program targeting Duchenne muscular dystrophy as a potential best-in-class therapy. The company pursues strategic partnerships with pharma/biotech companies for co-development of products.

Differentiator

Problem solved

Functional benefit

Products and services

• SPT Platform (Sapreme Technology Platform) Proprietary endosomal escape technology platform that enhances intracellular delivery of large molecule RNA therapeutics (ASOs and siRNAs) by mediating receptor-targeted delivery to endosomes and enabling pH-driven endosomal release. Used by Sapreme internally and offered to pharma/biotech partners through co-development arrangements to address the bottleneck of less than 1% of next-generation therapeutics crossing cellular barriers efficiently.
• Duchenne Muscular Dystrophy (DMD) Program Sapreme's lead therapeutic program designed as a potential best-in-class therapy for Duchenne muscular dystrophy (DMD), an incurable and fatal pediatric monogenic disease. The program leverages the SPT endosomal escape technology platform to enable intracellular delivery of RNA-based therapeutics to muscle tissue.

Quantifiable outcome

• Less than 1% of next-generation therapeutics cross cellular barriers efficiently without technology enhancement

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Select pharma/biotech companiescoreStrategic or Co-development PartnerSapreme is pursuing strategic partnerships to co-develop products with select pharma/biotech companies. The company mentions they are building a pipeline of therapeutic applications and are open to co-development arrangements with industry partners to advance their RNA therapeutics programs.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Entrada Therapeutics: Clinical-stage biotech developing endosomal-escape-enabled therapeutics for DMD and other neuromuscular diseases; directly comparable to Sapreme's SPT approach with overlapping DMD lead program and shared mechanistic thesis on intracellular delivery.
• Dyne Therapeutics: Clinical-stage biotech with the FORCE platform delivering oligonucleotides to muscle, heart and CNS for DMD, DM1, and FSHD. Closely aligned target tissues and indication focus make it a strong direct peer for Sapreme's extrahepatic delivery strategy.
• Arrowhead Pharmaceuticals: Develops RNAi therapeutics with the TRiM platform targeting multiple tissues including muscle and CNS, directly competing in extrahepatic oligonucleotide delivery and DMD-adjacent indications.
• Ionis Pharmaceuticals: Established antisense oligonucleotide (ASO) leader with multiple approved and clinical-stage programs. Highly comparable as a primary ASO developer that could be a customer or competitor for Sapreme's delivery technology.
• Sarepta Therapeutics: Commercial-stage leader in DMD therapeutics using PMO ASOs (eteplirsen, golodirsen, casimersen). Directly comparable target indication and oligonucleotide modality, representing the benchmark Sapreme's lead program aims to surpass.
• Wave Life Sciences: Develops stereopure oligonucleotide therapeutics using the PRISM platform across multiple tissues including muscle and CNS, including DMD programs. Directly comparable as a next-generation oligonucleotide developer with chemical-modification differentiation.

Broad incumbents

• Alnylam Pharmaceuticals: Commercial leader in siRNA therapeutics with the validated GalNAc liver-targeted delivery platform. Comparable as the dominant incumbent in oligonucleotide delivery, though Sapreme's extrahepatic focus and endosomal-escape mechanism differentiate Sapreme's niche.

Emerging players

• PepGen: Clinical-stage company developing cell-penetrating peptide-conjugated oligonucleotides for DMD and DM1. Comparable target indications and delivery-enhancement thesis, though PepGen uses peptide rather than triterpenoid chemistry.
• Avidity Biosciences: Clinical-stage company developing antibody-RNA conjugates (AOCs) for muscle and rare diseases, including DMD. Overlapping extrahepatic-delivery thesis and oligonucleotide payload focus make it a relevant emerging peer.
• Genevant Sciences: Develops lipid nanoparticle (LNP) and other delivery technologies for RNA therapeutics, including extrahepatic applications. Comparable as a delivery-platform peer addressing the same intracellular-delivery bottleneck Sapreme targets.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sapreme Technologies